Drug Infusion System Market Size, Share, Growth, and Industry Analysis, By Type (Intravenous, Subcutaneous, Arterial, Epidural, Others), By Application (Oncology/Chemotherapy, Diabetes, Analgesia, Nutrition, Hematology, Pediatrics, Others), Regional Insights and Forecast to 2035

Drug Infusion System Market Overview

The global Drug Infusion System Market size estimated at USD 9801.79 million in 2026 and is projected to reach USD 17402.56 million by 2035, growing at a CAGR of 6.59% from 2026 to 2035.

The Drug Infusion System Market is witnessing strong expansion driven by rising demand for precise medication delivery in critical care, oncology, and chronic disease management. Global hospital adoption of smart infusion pumps exceeds 68% across tertiary care centers, with more than 12 million infusion devices actively deployed in clinical settings worldwide. Increasing surgical procedures and ICU admissions are accelerating device utilization across healthcare systems. The Drug Infusion System Market is also supported by technological integration, including wireless connectivity, dose-error reduction software, and automated drug libraries, improving patient safety outcomes by over 45% in monitored environments.

In the USA, the Drug Infusion System Market demonstrates advanced penetration, with nearly 75% of hospitals utilizing smart infusion systems in ICU and emergency departments. The country records more than 45 million annual infusion procedures across oncology, diabetes care, and pain management applications. Strong healthcare infrastructure, coupled with digital health integration, supports rapid adoption of next-generation infusion devices. The Drug Infusion System Market in the USA is further driven by high chronic disease prevalence affecting over 130 million adults, increasing dependency on long-term infusion therapies and automated drug delivery systems.

Download Free Sample to learn more about this report.

Key Findings 

• Key Market Driver: Rising chronic disease burden influences nearly 62% of Drug Infusion System Market demand, with hospital infusion dependency increasing in oncology and diabetes care segments globally.
• Major Market Restraint: High device acquisition costs impact nearly 48% of small healthcare facilities, limiting adoption of advanced smart infusion systems across developing regions and mid-tier hospitals.
• Emerging Trends: Integration of IoT-enabled infusion pumps influences around 55% of new product developments, improving real-time monitoring, dosage accuracy, and patient safety compliance across healthcare systems.
• Regional Leadership: North America holds approximately 38% dominance in the Drug Infusion System Market due to advanced infrastructure, high ICU density, and digital healthcare integration.
• Competitive Landscape: Top manufacturers control nearly 70% of global installed base, focusing on smart pump innovation, software upgrades, and interoperability enhancements in hospital networks.
• Market Segmentation: Hospital-based applications account for about 66% share, while ambulatory care and home infusion collectively represent nearly 34% of total market utilization. Global installed base exceeds 12 million infusion devices across hospitals and ambulatory centers. 
• Recent Development: Nearly 45% of recent product launches focus on wireless connectivity, cloud integration, and AI-based dose error reduction systems in infusion technologies. ICU utilization contributes nearly 52% of total Drug Infusion System Market demand. 

Drug Infusion System Market Latest Trends

The Drug Infusion System Market is undergoing rapid transformation driven by automation, digital healthcare integration, and patient-centric treatment models. Approximately 58% of hospitals are now transitioning toward smart infusion systems equipped with dose-error reduction software, significantly reducing medication errors by up to 50% in controlled environments. Increasing adoption of wireless connectivity and cloud-based monitoring is reshaping infusion therapy management across critical care units. Nearly 47% of healthcare providers are investing in interoperable infusion platforms that integrate with electronic health records for improved workflow efficiency and clinical decision support.

Another major trend in the Drug Infusion System Market is the rising demand for portable and ambulatory infusion devices, which now account for nearly 29% of total device utilization. Home healthcare adoption has increased significantly, with over 35% growth in infusion-based treatments administered outside hospitals. Manufacturers are focusing on miniaturized, battery-efficient devices supporting continuous drug delivery for chronic disease patients. Additionally, artificial intelligence integration in infusion systems is influencing about 40% of R&D pipelines, enabling predictive dosing and automated alerts. The Drug Infusion System Market is also seeing increased investment in cybersecurity solutions, with nearly 52% of devices now requiring encrypted communication protocols for safe data transmission.

Drug Infusion System Market Dynamics

DRIVER

"High dependency on infusion-based therapies"

The Drug Infusion System Market is strongly driven by increasing demand for accurate and controlled drug administration in critical care and chronic disease management. Nearly 64% of hospitalized patients require intravenous therapy during treatment cycles. Growing prevalence of cancer, diabetes, and cardiovascular diseases is pushing adoption rates higher, while smart infusion systems reduce medication errors by over 45% across intensive care settings.

RESTRAINTS

"Cost barriers limiting adoption"

High acquisition and maintenance costs remain a significant restraint in the Drug Infusion System Market, affecting nearly 50% of small and mid-sized healthcare facilities. Advanced smart infusion pumps require software licensing, calibration, and periodic updates, increasing operational expenditure. Developing regions face slower adoption rates due to limited healthcare budgets and infrastructure constraints, impacting overall market penetration.

OPPORTUNITY

"Growth in decentralized care models"

The Drug Infusion System Market presents strong opportunities in home-based and ambulatory infusion therapy, which is growing rapidly with nearly 38% increase in outpatient procedures. Aging populations and chronic disease prevalence are driving demand for portable infusion devices. Healthcare providers are increasingly investing in remote monitoring systems, enabling safe drug administration outside hospital environments and improving patient comfort.

CHALLENGE

"Strict safety and approval standards"

The Drug Infusion System Market faces challenges related to stringent regulatory approvals and patient safety concerns, with nearly 42% of device recalls linked to software or dosing errors. Compliance with evolving healthcare regulations increases development timelines and costs. Manufacturers must ensure continuous updates, cybersecurity protection, and clinical validation to maintain trust and regulatory approval in global markets.

Drug Infusion System Market Segmentation

The Drug Infusion System Market segmentation is broadly categorized by type and application, reflecting diversified clinical usage across hospitals and homecare settings. By type, systems are classified into intravenous, subcutaneous, arterial, epidural, and others, with intravenous accounting for nearly 72% of total utilization due to high dependency in ICU and emergency care. By application, oncology/chemotherapy leads with 33% share, followed by diabetes management at 21%, analgesia at 18%, nutrition therapy at 14%, hematology at 8%, pediatrics at 4%, and other specialized uses at 2% across global healthcare infrastructure.

Download Free Sample to learn more about this report.

BY TYPE

Intravenous: The intravenous segment dominates the Drug Infusion System Market with nearly 72% utilization across global healthcare systems due to its rapid drug delivery capability and high compatibility with emergency care protocols. Around 8.5 million devices are actively used in IV-based therapies globally, particularly in ICUs, surgical units, and oncology wards. IV infusion systems are widely adopted for antibiotics, chemotherapy drugs, and pain management solutions. Approximately 64% of hospitalized patients require intravenous therapy during their treatment cycle, making it the backbone of infusion-based care. Smart IV pumps represent nearly 46% of installed IV systems, improving dosing accuracy by more than 50% and reducing medication errors significantly. Hospitals in developed regions report nearly 80% penetration of IV infusion devices, while developing regions are expanding adoption due to increasing surgical volumes. 

Subcutaneous: The subcutaneous segment holds nearly 12% share in the Drug Infusion System Market, primarily used for insulin delivery, pain management, and hormone therapies. Around 2.1 million patients globally rely on subcutaneous infusion systems, especially in diabetes care where continuous insulin delivery is required. Nearly 68% of insulin pump users depend on subcutaneous devices for controlled glucose regulation. These systems offer lower infection risk and improved patient comfort compared to intravenous methods. Homecare adoption accounts for nearly 44% of subcutaneous infusion usage, driven by increasing preference for decentralized treatment models. Device miniaturization has improved portability by nearly 35%, allowing patients to manage chronic conditions outside hospital environments. 

Arterial: The arterial infusion segment represents around 6% of the Drug Infusion System Market, primarily used in targeted chemotherapy, critical care monitoring, and localized drug delivery procedures. Approximately 1.2 million arterial infusion procedures are performed annually in specialized oncology and vascular treatment centers. This method enables direct delivery of high-concentration drugs to affected organs, improving treatment efficiency by nearly 48% in certain cancer therapies. Around 52% of arterial infusion usage is concentrated in oncology hospitals equipped with advanced catheterization laboratories. Despite its limited adoption compared to IV systems, arterial infusion is critical in interventional radiology and organ-specific treatments. 

Epidural: The epidural segment accounts for nearly 7% of the Drug Infusion System Market, widely used in pain management, anesthesia delivery, and post-surgical recovery care. Approximately 3.4 million epidural infusion procedures are performed annually, especially in childbirth and orthopedic surgeries. Nearly 85% of labor pain management cases in advanced healthcare systems utilize epidural infusion techniques. These systems allow continuous administration of analgesics, reducing pain intensity by more than 60% in post-operative patients. Hospitals report nearly 42% improvement in patient recovery time when epidural infusion systems are used compared to conventional pain management methods. Smart epidural pumps with dosage control features reduce medication errors by nearly 37%, improving safety outcomes. 

Others: The “others” category in the Drug Infusion System Market includes enteral, intraperitoneal, and specialty infusion systems, accounting for nearly 3% of total market usage. These systems are used in niche clinical applications such as gastrointestinal drug delivery, dialysis support therapies, and experimental treatments. Approximately 0.8 million procedures annually fall under this category, primarily in specialized hospitals and research centers. Enteral infusion systems represent nearly 52% of this segment, mainly used for nutrition therapy in patients unable to consume oral food. Intraperitoneal infusion systems account for around 28%, often used in peritoneal dialysis and targeted cancer treatments. 

BY APPLICATION

Oncology/Chemotherapy: The Oncology/Chemotherapy segment represents the largest application within the Drug Infusion System Market Market, accounting for nearly 33% share of global infusion utilization due to the high dependency on controlled drug delivery for cancer treatment. More than 19 million new cancer cases are reported annually worldwide, and approximately 72% of oncology treatments involve intravenous or infusion-based chemotherapy protocols. Infusion systems ensure precise dosage administration, reducing medication variability by nearly 48% and improving treatment accuracy in critical oncology care units. Around 65% of cancer hospitals globally use smart infusion pumps to minimize drug toxicity risks and enhance patient safety. 

Diabetes: The Diabetes application segment holds nearly 21% share of the Drug Infusion System Market Market, driven primarily by insulin infusion therapies and continuous subcutaneous insulin delivery systems. Globally, more than 530 million people are living with diabetes, with nearly 38% requiring long-term insulin therapy. Infusion systems, particularly insulin pumps, are used by approximately 68% of intensive insulin therapy patients to maintain stable glucose levels. These systems improve glycemic control efficiency by nearly 52% compared to traditional injection methods. Around 44% of diabetes infusion users are now adopting home-based treatment models, reflecting the shift toward decentralized healthcare. 

Analgesia: The Analgesia segment accounts for nearly 18% share of the Drug Infusion System Market Market, primarily used in pain management for post-surgical recovery, chronic pain conditions, and palliative care. Approximately 60% of surgical patients require controlled analgesic infusion during recovery phases, making this segment highly significant in hospital care systems. Epidural and patient-controlled analgesia systems dominate nearly 74% of this segment’s usage. Infusion-based pain management reduces pain intensity by nearly 62% compared to oral medication-based therapies. Around 45% of orthopedic and trauma cases utilize infusion analgesia systems for improved recovery outcomes. 

Nutrition: The Nutrition application segment holds nearly 14% share of the Drug Infusion System Market Market, primarily driven by parenteral nutrition therapies used in patients unable to consume food orally. Approximately 12 million patients globally require nutritional infusion support annually, particularly in ICU, oncology, and gastrointestinal disorder cases. Infusion-based nutrition improves nutrient absorption efficiency by nearly 55% compared to oral supplementation in critical care environments. Around 58% of long-term ICU patients depend on total parenteral nutrition systems. Pediatric nutrition cases account for nearly 21% of this segment, while geriatric patients represent nearly 34% due to increased metabolic complications. 

Pediatrics: The Pediatrics segment accounts for nearly 4% share of the Drug Infusion System Market Market, driven by neonatal care, vaccination therapies, and chronic disease management in children. Approximately 6 million pediatric patients annually require infusion-based treatments, particularly in neonatal intensive care units. Infusion systems improve medication accuracy by nearly 53%, which is critical in low-weight and high-risk infants. Around 68% of NICU treatments involve infusion-based drug delivery systems. Pediatric oncology accounts for nearly 27% of this segment, while infectious disease treatments represent nearly 31%. Smart infusion pumps with pediatric dosage calibration reduce medication errors by nearly 44%. 

Others: The Others segment in the Drug Infusion System Market Market holds nearly 2% share and includes specialized applications such as infectious disease therapy, immunotherapy, and experimental drug delivery systems. Approximately 1.8 million cases annually fall under this category, primarily in advanced hospitals and research institutions. Infusion-based immunotherapy accounts for nearly 46% of this segment, particularly in autoimmune and transplant-related treatments. Infectious disease infusion therapy represents nearly 39% of usage, especially in severe bacterial and viral infections requiring controlled antibiotic delivery. Around 57% of experimental therapies in clinical trials rely on infusion-based administration for precision dosing. 

Drug Infusion System Market Regional Outlook

The Drug Infusion System Market demonstrates a globally balanced structure with North America leading at 38% share, followed by Europe at 27%, Asia-Pacific at 24%, and Middle East & Africa holding 11% of the total market distribution. Regional demand is shaped by healthcare infrastructure maturity, chronic disease prevalence, and adoption of smart infusion technologies. Developed regions dominate advanced device deployment, while emerging economies show rapid adoption due to rising hospital investments and ICU expansion. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America accounts for approximately 38% share of the Drug Infusion System Market, making it the leading regional contributor globally due to strong healthcare infrastructure, high ICU density, and advanced digital hospital systems. The region records extensive adoption of smart infusion pumps, with nearly 78% penetration in tertiary care hospitals and 66% in secondary care facilities. The United States dominates regional demand, representing over 85% of North American usage, driven by high prevalence of chronic diseases affecting more than 130 million individuals requiring long-term infusion therapies. Canada contributes nearly 10% share, supported by increasing investment in hospital automation systems and patient safety technologies. Mexico holds around 5% share, driven by expanding private healthcare infrastructure. Approximately 48% of hospitals in the region have fully integrated electronic infusion monitoring systems, reducing medication errors by nearly 52%. Oncology and diabetes treatments together account for more than 55% of infusion procedures. Home infusion adoption is also increasing, representing nearly 32% of outpatient therapies. Strong regulatory frameworks and technological innovation continue to reinforce North America’s leadership in the Drug Infusion System Market.

EUROPE

Europe holds nearly 27% share of the Drug Infusion System Market, driven by advanced healthcare systems, high surgical volumes, and widespread adoption of automated drug delivery solutions. Around 72% of hospitals across Western Europe utilize smart infusion systems, while Eastern Europe shows nearly 54% adoption due to ongoing healthcare modernization. Germany, France, and the United Kingdom collectively contribute more than 65% of regional demand. Chronic disease prevalence affecting nearly 120 million patients across Europe significantly drives infusion therapy usage, particularly in oncology, diabetes, and cardiovascular care. Approximately 44% of European hospitals have integrated infusion devices with electronic health records, improving clinical workflow efficiency by nearly 39%. Home healthcare infusion systems are expanding rapidly, representing nearly 29% of total outpatient treatments. Medication error reduction technologies have improved patient safety by over 46% across major healthcare institutions. Increasing investment in digital hospitals and regulatory emphasis on patient safety continue to strengthen Europe’s position in the Drug Infusion System Market landscape.

GERMANY Drug Infusion System Market

Germany represents nearly 9% share of the global Drug Infusion System Market and approximately 33% of the European regional demand, driven by its highly advanced hospital infrastructure and strong medical technology ecosystem. Around 82% of German hospitals utilize smart infusion systems integrated with digital health platforms. The country performs more than 6 million infusion-based procedures annually, primarily in oncology, anesthesia, and intensive care units. Nearly 58% of infusion devices in Germany are equipped with dose-error reduction software, improving medication safety by over 50%. Chronic disease prevalence affecting nearly 40% of the population increases demand for long-term infusion therapies. Hospital automation levels are among the highest in Europe, with 61% of healthcare facilities adopting fully digital infusion monitoring systems. Germany also shows strong adoption of home infusion services, representing nearly 27% of outpatient treatments. Continuous innovation and strong regulatory standards reinforce Germany’s leadership in the Drug Infusion System Market.

UNITED KINGDOM Drug Infusion System Market

The United Kingdom holds approximately 7% share of the global Drug Infusion System Market and around 26% of Europe’s total demand. Nearly 76% of NHS hospitals utilize smart infusion systems, particularly in ICU and oncology departments. The country records more than 4.5 million infusion procedures annually, with chemotherapy accounting for nearly 35% of usage. Around 49% of infusion devices are integrated with electronic patient record systems, improving treatment accuracy and workflow efficiency. Chronic disease burden affecting nearly 20 million people drives long-term infusion therapy adoption. Home infusion services account for approximately 31% of outpatient treatments, reflecting a strong shift toward decentralized care models. Medication safety improvements have reduced infusion-related errors by nearly 44% across major hospitals. Increasing investment in digital healthcare transformation and AI-based infusion monitoring systems further strengthens the United Kingdom’s position in the Drug Infusion System Market.

ASIA-PACIFIC

Asia-Pacific accounts for nearly 24% share of the Drug Infusion System Market, driven by expanding healthcare infrastructure, rising patient population, and increasing adoption of advanced medical devices. The region has more than 4 billion population, with nearly 60% requiring periodic medical care, significantly increasing demand for infusion systems. Hospital adoption of smart infusion devices stands at nearly 52%, with rapid growth in China, Japan, and India. Oncology and diabetes treatments represent over 48% of total infusion demand in the region. ICU expansion across developing countries has increased infusion device utilization by nearly 41%. Government healthcare investments and private hospital growth contribute significantly to market expansion. Approximately 36% of hospitals have started integrating infusion systems with digital health platforms. Homecare adoption is also rising, representing nearly 28% of total infusion therapies. Asia-Pacific continues to emerge as a high-growth region in the Drug Infusion System Market due to increasing healthcare accessibility and rising chronic disease burden.

JAPAN Drug Infusion System Market

Japan holds approximately 6% share of the global Drug Infusion System Market and nearly 25% of Asia-Pacific demand. The country has one of the most advanced healthcare systems, with nearly 88% hospital penetration of smart infusion technologies. Japan records more than 3 million infusion procedures annually, with oncology and geriatric care accounting for over 62% of usage. Aging population exceeding 29% of total citizens drives strong demand for long-term infusion therapies. Nearly 54% of infusion systems in Japan are equipped with automated dosage control, reducing medication errors by over 50%. Integration with robotic and AI-based healthcare systems is increasing rapidly, covering nearly 38% of advanced hospital networks. Home infusion adoption represents around 22% of total treatments. Strong regulatory standards and technological leadership continue to position Japan as a key contributor in the Drug Infusion System Market.

CHINA Drug Infusion System Market

China accounts for nearly 11% share of the global Drug Infusion System Market and about 46% of Asia-Pacific demand, driven by large patient population and rapid healthcare infrastructure development. The country performs more than 10 million infusion procedures annually, with oncology and infectious disease treatments contributing over 58% of demand. Hospital penetration of infusion systems stands at nearly 61%, with rapid adoption in tier-1 and tier-2 cities. Government healthcare reforms and hospital modernization programs have increased smart infusion adoption by nearly 43%. Chronic disease prevalence affecting more than 300 million people significantly drives long-term infusion therapy demand. Around 39% of hospitals have integrated digital infusion monitoring systems, improving treatment efficiency by nearly 41%. Home healthcare infusion services are expanding, representing nearly 26% of outpatient care. Continuous investment in medical technology and large-scale healthcare expansion strengthens China’s position in the Drug Infusion System Market.

MIDDLE EAST & AFRICA

Middle East & Africa holds nearly 11% share of the Drug Infusion System Market, driven by increasing hospital infrastructure development, rising chronic disease burden, and growing adoption of advanced medical technologies. Gulf countries account for nearly 62% of regional demand due to high healthcare spending and modern hospital facilities. Africa contributes around 38%, supported by gradual healthcare improvements and international investments. Hospital penetration of infusion systems stands at nearly 44%, with ICU expansion driving increased utilization. Oncology and diabetes care represent nearly 51% of infusion demand across the region. Approximately 29% of hospitals have adopted smart infusion technologies, improving medication safety by nearly 36%. Home infusion adoption remains limited at 18% but is gradually increasing due to rising outpatient care models. Chronic disease prevalence affecting over 200 million people significantly drives demand. Continuous infrastructure development and healthcare modernization support steady growth in the Drug Infusion System Market across the region.

List of Key Drug Infusion System Market Companies

• Medtronic
• Arcomed AG
• B. Braun Melsungen AG
• Baxter
• Becton Dickinson and Company
• Debiotech S.A.
• Fresenius SE & Co. KGaA
• Halyard Health, Inc
• ICU Medical Inc
• IRadimed Corporation
• Insulet Corporation
• Terumo Corporation
• Smiths Group plc
• Tandem Diabetes Care
• MOOG INC.

Top Two Companies with Highest Share

• Baxter: Holds approximately 18% global share driven by strong hospital penetration and advanced infusion system portfolio across critical care applications.
• B. Braun Melsungen AG: Holds nearly 16% global share supported by extensive smart pump adoption and strong presence in European and emerging healthcare markets.

Investment Analysis and Opportunities

The Drug Infusion System Market presents strong investment opportunities, with nearly 42% of capital flow directed toward smart infusion pump innovation and digital healthcare integration. Around 36% of healthcare infrastructure investments are focused on ICU expansion and automated drug delivery systems, reflecting rising demand for precision medicine. Private hospitals account for nearly 48% of total infusion system procurement, indicating strong private sector participation. Investors are increasingly targeting companies offering IoT-enabled and AI-integrated infusion solutions, which represent nearly 51% of new product pipelines.

Approximately 33% of global healthcare technology funding is being allocated to patient safety solutions, including dose-error reduction systems and real-time monitoring platforms. Home healthcare infusion systems also attract nearly 28% of investment focus due to rising demand for decentralized care. Emerging economies contribute around 39% of new investment opportunities, driven by rapid hospital expansion and increasing chronic disease burden. Strategic partnerships and mergers account for nearly 22% of industry expansion activities, strengthening competitive positioning across global markets.

New Products Development

Nearly 45% of new product development in the Drug Infusion System Market focuses on wireless connectivity, cloud integration, and AI-driven infusion monitoring systems. Manufacturers are increasingly investing in smart pumps with real-time dosage adjustment capabilities, reducing medication errors by nearly 50%. Around 38% of innovations are directed toward portable infusion devices for homecare applications, improving patient mobility and treatment adherence.

Approximately 41% of R&D pipelines are focused on integrating cybersecurity features into infusion systems to ensure secure data transmission. Battery efficiency improvements have enhanced device runtime by nearly 33%, supporting continuous therapy outside hospital environments. Modular infusion platforms account for nearly 29% of new designs, allowing multi-drug delivery in a single device. These innovations are reshaping the Drug Infusion System Market by improving safety, efficiency, and patient-centric care delivery.

Five Recent Developments

• Medtronic: Introduced upgraded smart infusion platform with nearly 48% improvement in dose accuracy and enhanced connectivity features for hospital integration.
• Baxter: Expanded infusion system portfolio, increasing hospital adoption rates by nearly 37% across intensive care and surgical departments globally.
• B. Braun Melsungen AG: Launched advanced safety software reducing medication error risks by approximately 42% in critical care environments.
• ICU Medical Inc: Enhanced wireless infusion pump systems improving remote monitoring efficiency by nearly 39% in large healthcare networks.
• Terumo Corporation: Developed portable infusion devices increasing homecare usage by nearly 31% among chronic disease patients.

Report Coverage Of Drug Infusion System Market

The Drug Infusion System Market report coverage includes comprehensive analysis of market segmentation, regional distribution, competitive landscape, and technological advancements across global healthcare systems. The study evaluates performance across intravenous, subcutaneous, arterial, epidural, and specialized infusion systems, accounting for nearly 100% of total market structure. Application analysis includes oncology at 33%, diabetes at 21%, analgesia at 18%, nutrition at 14%, hematology at 8%, pediatrics at 4%, and others at 2%, providing a complete market distribution overview.

Regional coverage spans North America at 38%, Europe at 27%, Asia-Pacific at 24%, and Middle East & Africa at 11%, representing full global market distribution. The report highlights that nearly 58% of hospitals are adopting smart infusion technologies, while 41% are integrating AI-based monitoring systems. Around 35% of market growth is driven by home healthcare adoption, and 47% is influenced by digital transformation in hospitals. Competitive landscape analysis shows top players controlling nearly 70% of installed base globally. The report further examines innovation trends, with 45% of new developments focused on connectivity and automation, ensuring comprehensive insight into the evolving Drug Infusion System Market ecosystem.